Tyra Biosciences is a clinical-stage biotechnology company developing next-generation precision medicines targeting FGFR biology for oncology and genetically defined conditions. Its lead product, oral dabogratinib (formerly TYRA-300), is an FGFR3-selective inhibitor in Phase 2 trials for low-grade upper tract urothelial carcinoma, intermediate risk non-muscle invasive bladder cancer, and achondroplasia. The company also has TYRA-430 (FGFR4/3 biased, Phase 1 for HCC) and TYRA-200 (FGFR1/2/3 inhibitor, Phase 1 for ICC). All assets are developed in-house using its proprietary SNP platform.
expected 2026-12-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-02 | 2025-12-31 | 0001193125-26-085490 | EDGAR | 87K words |
| 2025-03-27 | 2024-12-31 | 0000950170-25-046124 | EDGAR | 88K words |
| 2024-03-19 | 2023-12-31 | 0000950170-24-033461 | EDGAR | 96K words |
| 2023-03-22 | 2022-12-31 | 0000950170-23-009181 | EDGAR | 95K words |
| 2022-03-03 | 2021-12-31 | 0000950170-22-002814 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-04 | 2026-06-30 | 0001193125-26-332995 | EDGAR | 18K words |
| 2025-11-05 | 2025-09-30 | 0001193125-25-266967 | EDGAR | 18K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108899 | EDGAR | 18K words |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066942 | EDGAR | 17K words |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123346 | EDGAR | 19K words |
| 2024-08-07 | 2024-06-30 | 0000950170-24-092778 | EDGAR | 18K words |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056971 | EDGAR | 16K words |
| 2023-11-07 | 2023-09-30 | 0000950170-23-060276 | EDGAR | 16K words |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041382 | EDGAR | 16K words |
| 2023-05-04 | 2023-03-31 | 0000950170-23-017875 | EDGAR | 14K words |
| 2022-11-03 | 2022-09-30 | 0000950170-22-021937 | EDGAR | 17K words |
| 2022-08-04 | 2022-06-30 | 0000950170-22-014802 | EDGAR | 15K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-15 | 0001193125-26-390951 | EDGAR | 1K words |
| 2026-09-09 | 0001193125-26-385886 | EDGAR | 2K words |
| 2026-08-04 | 0001193125-26-332752 | EDGAR | 3K words |
| 2026-04-02 | 0001193125-26-140027 | EDGAR | 1K words |
| 2026-03-04 | 0001193125-26-091880 | EDGAR | 1K words |
| 2026-03-02 | 0001193125-26-085399 | EDGAR | 3K words |
| 2025-12-01 | 0001193125-25-303162 | EDGAR | 1K words |
| 2025-11-05 | 0001193125-25-266916 | EDGAR | 3K words |
| 2025-08-22 | 0001193125-25-185553 | EDGAR | 1K words |
| 2025-08-14 | 0000950170-25-108876 | EDGAR | 3K words |
72 total filings indexed. 45 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001863127 |
| Ticker | TYRA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.tyra.bio |
| Listed | 2021-09-15 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/TYRA (~200 tokens, structured JSON with cryptographic provenance)